Dominique Heymann

Summary

Country: France

Publications

  1. pmc Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients
    M Chemel
    INSERM, UMR 957, France
    Ann Rheum Dis 71:150-4. 2012
  2. ncbi request reprint Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools
    Dominique Heymann
    Pathophysiology of Bone Resorption Laboratory and Therapy of Primitive Bone Tumors, EA3822, INSERM ERI 7, Medicine Faculty, 1 rue Gaston Veil, 44035 Nantes cedex 1, France
    Drug Discov Today 10:242-7. 2005
  3. pmc Autophagy: A protective mechanism in response to stress and inflammation
    Dominique Heymann
    INSERM, ERI 7, Nantes F 44035, France
    Curr Opin Investig Drugs 7:443-50. 2006
  4. doi request reprint Inhibition of osteolysis and increase of bone formation after local administration of siRNA-targeting RANK in a polyethylene particle-induced osteolysis model
    L A Córdova
    INSERM, UMR 957, 1 rue Gaston Veil, 44035 Nantes cedex 1, France University of Nantes, Nantes Atlantique Universities, Laboratory of Pathophysiology of Bone Resorption and Therapy of Primary Bone Tumours, 1 rue Gaston Veil, 44035 Nantes cedex 1, France Department of Oral and Maxillofacial Surgery, San Borja Arriaran University Hospital, Faculty of Dentistry, University of Chile CONICYT, Sergio Livingstone Polhammer 943, Independencia, Santiago, Chile Electronic address
    Acta Biomater 13:150-8. 2015
  5. pmc The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumour Growth and also a Source of New Therapeutic Targets
    E David
    INSERM, UMR 957, Physiopathologie de la Resorption Osseuse et Therapie des Tumeurs Osseuses Primitives, Faculte de Medecine, 1 rue Gaston Veil, 44035 Nantes cedex 1, 44035 Nantes, France
    Sarcoma 2011:932451. 2011
  6. pmc 99mTc-NTP 15-5 assessment of the early therapeutic response of chondrosarcoma to zoledronic acid in the Swarm rat orthotopic model
    Elisabeth Miot-Noirault
    Inserm UMR 990, Universite d Auvergne, BP 184, rue Montalembert, Clermont Ferrand, Cedex, 63005, France
    EJNMMI Res 3:40. 2013
  7. pmc Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma
    S Theoleyre
    INSERM ERI 7 EA 3822, Physiopathologie de la Resorption Osseuse et Therapie des Tumeurs Osseuses Primitives, Faculte de Medecine, 1 rue Gaston Veil, 44035 Nantes cedex 1, France
    BMC Cancer 5:123. 2005
  8. ncbi request reprint Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid
    Francois Lamoureux
    INSERM, ERI 7, Nantes, France
    Int J Cancer 122:751-60. 2008
  9. doi request reprint Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival
    Gaëlle Picarda
    Institut National de la Sante et de la Recherche Medicale UMR_S 957, Université de Nantes EA 3822, Nantes Atlantique Universites, Physiopathologie de la Resorption Osseuse et Therapie des Tumeurs Osseuses Primitives, Nantes, France
    Clin Cancer Res 16:2363-74. 2010
  10. doi request reprint Direct anti-cancer effect of oncostatin M on chondrosarcoma
    Emmanuelle David
    INSERM, U957, Nantes, France
    Int J Cancer 128:1822-35. 2011

Collaborators

Detail Information

Publications90

  1. pmc Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients
    M Chemel
    INSERM, UMR 957, France
    Ann Rheum Dis 71:150-4. 2012
    ..Interleukin (IL) 34 is a new cytokine implicated in macrophage differentiation and osteoclastogenesis. This study assessed IL-34 expression in the tissue of patients with rheumatoid arthritis (RA)...
  2. ncbi request reprint Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools
    Dominique Heymann
    Pathophysiology of Bone Resorption Laboratory and Therapy of Primitive Bone Tumors, EA3822, INSERM ERI 7, Medicine Faculty, 1 rue Gaston Veil, 44035 Nantes cedex 1, France
    Drug Discov Today 10:242-7. 2005
    ....
  3. pmc Autophagy: A protective mechanism in response to stress and inflammation
    Dominique Heymann
    INSERM, ERI 7, Nantes F 44035, France
    Curr Opin Investig Drugs 7:443-50. 2006
    ..This review provides an overview of autophagy and discusses its regulation, function and future therapeutic possibilities, with a focus on the role of autophagy in inflammation...
  4. doi request reprint Inhibition of osteolysis and increase of bone formation after local administration of siRNA-targeting RANK in a polyethylene particle-induced osteolysis model
    L A Córdova
    INSERM, UMR 957, 1 rue Gaston Veil, 44035 Nantes cedex 1, France University of Nantes, Nantes Atlantique Universities, Laboratory of Pathophysiology of Bone Resorption and Therapy of Primary Bone Tumours, 1 rue Gaston Veil, 44035 Nantes cedex 1, France Department of Oral and Maxillofacial Surgery, San Borja Arriaran University Hospital, Faculty of Dentistry, University of Chile CONICYT, Sergio Livingstone Polhammer 943, Independencia, Santiago, Chile Electronic address
    Acta Biomater 13:150-8. 2015
    ..Our findings show that RANK siRNA delivered locally by a synthetic vector may be an effective approach for reducing osteolysis and may even stimulate bone formation in aseptic loosening of prosthetic implants...
  5. pmc The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumour Growth and also a Source of New Therapeutic Targets
    E David
    INSERM, UMR 957, Physiopathologie de la Resorption Osseuse et Therapie des Tumeurs Osseuses Primitives, Faculte de Medecine, 1 rue Gaston Veil, 44035 Nantes cedex 1, 44035 Nantes, France
    Sarcoma 2011:932451. 2011
    ..The present paper aims to summarize the main evidence sustaining the existence of a specific bone niche in the pathogenesis of chondrosarcomas...
  6. pmc 99mTc-NTP 15-5 assessment of the early therapeutic response of chondrosarcoma to zoledronic acid in the Swarm rat orthotopic model
    Elisabeth Miot-Noirault
    Inserm UMR 990, Universite d Auvergne, BP 184, rue Montalembert, Clermont Ferrand, Cedex, 63005, France
    EJNMMI Res 3:40. 2013
    ....
  7. pmc Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma
    S Theoleyre
    INSERM ERI 7 EA 3822, Physiopathologie de la Resorption Osseuse et Therapie des Tumeurs Osseuses Primitives, Faculte de Medecine, 1 rue Gaston Veil, 44035 Nantes cedex 1, France
    BMC Cancer 5:123. 2005
    ..While TIL represent a fascinating therapeutic approach in numerous malignant pathologies, there is few report concerning adult bone-associated tumors including osteosarcoma...
  8. ncbi request reprint Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid
    Francois Lamoureux
    INSERM, ERI 7, Nantes, France
    Int J Cancer 122:751-60. 2008
    ....
  9. doi request reprint Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival
    Gaëlle Picarda
    Institut National de la Sante et de la Recherche Medicale UMR_S 957, Université de Nantes EA 3822, Nantes Atlantique Universites, Physiopathologie de la Resorption Osseuse et Therapie des Tumeurs Osseuses Primitives, Nantes, France
    Clin Cancer Res 16:2363-74. 2010
    ....
  10. doi request reprint Direct anti-cancer effect of oncostatin M on chondrosarcoma
    Emmanuelle David
    INSERM, U957, Nantes, France
    Int J Cancer 128:1822-35. 2011
    ..Its side effect on bone remodeling could be managed with anti-resorption agents, thus offering potential new lines of therapeutic interventions...
  11. doi request reprint Long term oncostatin M treatment induces an osteocyte-like differentiation on osteosarcoma and calvaria cells
    Bénédicte Brounais
    INSERM, ERI 7, Nantes, F 44035, France
    Bone 44:830-9. 2009
    ..Moreover, OSM-over-expressing osteoblastic cells differentiate into osteocyte-like cells, the major cellular contingent in bone, providing new culture conditions for this cell type which is difficult to obtain in vitro...
  12. doi request reprint A Disintegrin And Metalloproteinase 12 produced by tumour cells accelerates osteosarcoma tumour progression and associated osteolysis
    Steven Georges
    LUNAM Université, France INSERM, UMR S 957, Nantes, France Université de NANTES, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France CHU de Nantes, Nantes, France Equipe labellisée Ligue contre le Cancer 2012, Nantes, France
    Eur J Cancer 49:2253-63. 2013
    ..Metalloproteinases decisively contribute to cancer development and promotion by regulating cell growth, angiogenesis or inflammation. However, their role in osteosarcoma remains still unknown...
  13. pmc Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma
    Francois Lamoureux
    INSERM, ERI 7, Universite de Nantes, Nantes Atlantique Universites, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, EA3822, 1 rue Gaston Veil, 44035 Nantes cedex 1, France
    Mol Cancer Ther 7:3389-98. 2008
    ..Furthermore, mRANK-Fc has no direct activity on osteosarcoma cells in vitro. mRANK-Fc exerts an indirect inhibitory effect on osteosarcoma progression through inhibition of bone resorption...
  14. doi request reprint Oncostatin M is a growth factor for Ewing sarcoma
    Emmanuelle David
    INSERM, UMR, Ligue Team 2012, Nantes, France
    Am J Pathol 181:1782-95. 2012
    ..Thus, this study on rare bone malignancies gives valuable insights on more common cancer regulatory mechanisms and could provide new therapeutic opportunities...
  15. doi request reprint Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling
    Pierre Guihard
    INSERM, UMR 957, Equipe Labellisée LIGUE 2012, Nantes, France
    Stem Cells 30:762-72. 2012
    ....
  16. doi request reprint Osteoprotegerin: multiple partners for multiple functions
    Marc Baud'huin
    INSERM, UMR957, Nantes F 44035, France Université de NANTES, Nantes Atlantique Universites, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes F 44035, France CHU, Hotel Dieu, Nantes, France Electronic address
    Cytokine Growth Factor Rev 24:401-9. 2013
    ..This review describes an overview of the different OPG ligands regulating its biological functions. ..
  17. doi request reprint Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma
    Francois Lamoureux
    Faculte de Medecine, Laboratoire de Physiopathologie de la Résorption Osseuse, Institut National de la Sante et de la Recherche Medicale ERI 7, Universite de Nantes, Nantes Cedex 1, France
    Cancer Res 69:526-36. 2009
    ..However, as GAGs inhibit OPG 1-401 but not OPG 1-194 binding to TRAIL or to RANKL, they may represent potent regulators of OPG availability and antitumor activity in bone tumor microenvironment...
  18. doi request reprint Glycosaminoglycans inhibit the adherence and the spreading of osteoclasts and their precursors: role in osteoclastogenesis and bone resorption
    Marc Baud'huin
    INSERM, UMR S 957, Nantes F 44035, France
    Eur J Cell Biol 90:49-57. 2011
    ..The present work clearly evidences that GAGs inhibit osteoclastogenesis in vitro and strengthens the therapeutic interest of defined GAGs in osteolytic diseases...
  19. ncbi request reprint Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption
    Francois Lamoureux
    Institut National de la Sante et de la Recherche Medicale INSERM, ERI 7, Universite de Nantes, Nantes Atlantique Universites, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France
    Cancer Res 67:7308-18. 2007
    ....
  20. doi request reprint Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis
    Marc Baud'huin
    INSERM, UMR S 957, Nantes F 44035, France
    J Pathol 221:77-86. 2010
    ..Overall, these data reveal that IL-34 can be entirely substituted for M-CSF in RANKL-induced osteoclastogenesis, thus identifying a new biological activity for this cytokine and a contribution to the pathogenesis of GCTs...
  21. pmc Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival
    Marc Baud'huin
    INSERM U957, Universite de Nantes, Nantes Atlantique Universites, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes F 44035, France
    J Biol Chem 284:31704-13. 2009
    ..vWF complex on osteoclasts and on induced cell apoptosis, pointing out its potential involvement in physiological bone remodeling or in bone damages associated with severe hemophilia and cancer development...
  22. doi request reprint Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients
    Guillaume A Odri
    Institut National de la Santé et de la Recherche Médicale U957, Nantes, France
    Cancer Res 70:7610-9. 2010
    ..This very promising result could allow clinicians to diminish the doses of chemotherapy...
  23. doi request reprint NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate
    Bérengère Gobin
    INSERM, UMR 957, Equipe LIGUE Nationale Contre le Cancer 2012, Nantes 44035, France Université de NANTES, Nantes Atlantique Universites, Pathophysiology of Bone Resorption and Therapy of Primary Bone Tumors, Nantes, France
    Cancer Lett 344:291-8. 2014
    ..Taken together, the results of the present work show that NVP-BEZ235 exhibits therapeutic interest in osteosarcoma and may be a promising adjuvant drug for bone sarcomas...
  24. ncbi request reprint OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation
    Steeve Kwan Tat
    INSERM, ERI 7, Nantes F 44035, France
    Bone 39:706-15. 2006
    ..Reciprocally, this modulation contributes to reduce the bioavailability of OPG...
  25. doi request reprint Oncostatin M induces bone loss and sensitizes rat osteosarcoma to the antitumor effect of Midostaurin in vivo
    Bénédicte Brounais
    INSERM, ERI 7, Nantes, France
    Clin Cancer Res 14:5400-9. 2008
    ..Moreover, OSM sensitizes these cells to apoptosis driven by various death inducers such as the kinase inhibitor staurosporine. Here, we asked whether OSM would have similar effects in vivo...
  26. ncbi request reprint Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells
    Kanji Mori
    Universite de Nantes, Nantes Atlantique Universites, Laboratoire de Physiopathologie de Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, EA3822, Nantes, F 44035, France
    Oncol Rep 18:1365-71. 2007
    ..Our results strengthen the involvement of the RANK/RANKL/OPG axis in osteosarcoma biology and capability to identify novel therapeutic approaches targeting RANK-positive osteosarcomas...
  27. ncbi request reprint Novel anti-cancer strategy in bone tumors by targeting molecular and cellular modulators of bone resorption
    Bénédicte Brounais
    INSERM, ERI 7, Nantes, F 44035 France
    Recent Pat Anticancer Drug Discov 3:178-86. 2008
    ....
  28. doi request reprint Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3
    Laurence Duplomb
    EA3822 INSERM 7, ERI 7, and Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Universite de Nantes, 1 rue Gaston Veil, Nantes Cedex 1, France
    Endocrinology 149:3688-97. 2008
    ....
  29. pmc Conditioned media from mouse osteosarcoma cells promote MC3T3-E1 cell proliferation using JAKs and PI3-K/Akt signal crosstalk
    Kanji Mori
    INSERM, Nantes, France
    Cancer Sci 99:2170-6. 2008
    ....
  30. pmc Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process
    Gatien Moriceau
    INSERM, UMR 957, Nantes, France
    Cancer Res 70:10329-39. 2010
    ..Our findings rationalize further study of the applications of mTOR and mevalonate pathway inhibitors that can limit protein prenylation pathways...
  31. doi request reprint Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient
    Severine Battaglia
    INSERM, UMR 957, Nantes, France
    J Bone Miner Res 26:2439-51. 2011
    ....
  32. ncbi request reprint The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling
    Sandrine Theoleyre
    EA 3822, Inserm ESPRI, Physiopathologie de la Resorption Osseuse et Therapie des Tumeurs Osseuses Primitives, Faculte de Medecine, 1 rue Gaston Veil, 44035 Nantes cedex 1, France
    Cytokine Growth Factor Rev 15:457-75. 2004
    ..Kwan Tat S, Padrines M, Theoleyre S, Heymann D, Fortun Y. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004;15:49-60]...
  33. ncbi request reprint RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells
    Yohann Wittrant
    Université de Nantes EA 3822, INSERM ERI 7, Physiopathologie de la Resorption Osseuse et Therapie des Tumeurs Osseuses Primitives, Faculte de Medecine, 44035 Nantes cedex 1, France
    Int J Oncol 28:261-9. 2006
    ..This is the first report describing a functional RANK expressed on osteosarcoma cells, as shown by its ability to induce signal transduction pathways and biological activity when stimulated by RANKL...
  34. doi request reprint Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth
    Gatien Moriceau
    National Institute of Health and Medical Research, Nantes, France
    Cancer 118:750-60. 2012
    ....
  35. doi request reprint Role of the OPG/RANK/RANKL triad in calcifications of the atheromatous plaques: comparison between carotid and femoral beds
    Marie Françoise Heymann
    INSERM, UMR 957, Nantes F 44035, France
    Cytokine 58:300-6. 2012
    ..These data strengthen the key role played by OPG in the differential calcification in carotid and femoral plaques...
  36. doi request reprint Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models
    Julie Rousseau
    INSERM, U957, Nantes, France
    J Bone Miner Res 26:2452-62. 2011
    ..Moreover, the Rankl inhibition mediated by RNA interference strategy improves the therapeutic response of primary osteosarcoma to chemotherapy...
  37. pmc Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1
    Camille Jacques
    INSERM, UMR 957, Equipe Labellisée LIGUE 2012, Nantes, France
    Oncotarget 7:24125-40. 2016
    ..Taken together, our data indicate that inhibiting the BET bromodomains interferes with EWS-FLi1 transcription and could be a promising strategy in the Ewing tumors context. ..
  38. doi request reprint Oncostatin m, an inflammatory cytokine produced by macrophages, supports intramembranous bone healing in a mouse model of tibia injury
    Pierre Guihard
    INSERM, UMR 957, Ligue Team 2012, Nantes, France Pathophysiology of Bone Resorption Laboratory and Therapy of Primary Bone Tumors, Medicine Faculty, Universite de Nantes, Nantes Atlantique Universites, Nantes, France
    Am J Pathol 185:765-75. 2015
    ..Because bone resorption is largely unaltered, OSM could represent a new anabolic treatment for unconsolidated bone fractures. ..
  39. pmc Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence
    Pierre Perrot
    INSERM, U957, Nantes, France
    PLoS ONE 5:e10999. 2010
    ..For correction of soft tissue defect consecutive to surgery and/or tumor treatment, autologous fat graft has been proposed in plastic and reconstructive surgery...
  40. doi request reprint Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression
    Benjamin Ory
    Universite de Nantes, Nantes Atlantique Universites, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France INSERM, UMR 957, Nantes, France LUNAM Université, Nantes, France Equipe labellisée LIGUE 2012, Nantes, France
    Clin Cancer Res 22:2520-33. 2016
    ..We assessed the antitumor properties of a synthetic HSP90 inhibitor, PF4942847, alone or in combination with zoledronic acid in osteosarcoma...
  41. doi request reprint BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma
    Bérengère Gobin
    INSERM, UMR 957, Nantes, 44035, France Université de NANTES, Physiopathologie de la Resorption Osseuse et Therapie des Tumeurs Osseuses Primitives, Nantes, 44035, France
    Int J Cancer 136:784-96. 2015
    ..BYL719 also exhibited dual activities on osteoblast and osteoclast differentiation. Overall, the present work shows that BYL719 is a promising drug in either a single or multidrug approach to curing bone sarcoma...
  42. doi request reprint Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma?
    Francoise Redini
    INSERM, UMR 957, Equipe Ligue Contre le Cancer 2012, Nantes, F 44035, France
    Expert Opin Emerg Drugs 18:339-52. 2013
    ..For these high risk patients, new therapeutic approaches are needed beyond conventional therapies (chemotherapy, surgery and radiation) such as targeted therapies...
  43. ncbi request reprint Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3
    Céline Chipoy
    Laboratory of Pathophysiology of Bone Resorption and Therapy of Primitive Bone Tumors, Inserm ESPRI, Nantes, France
    J Bone Miner Res 19:1850-61. 2004
    ..OSM downregulates osteoblast markers but induces the glial fibrillary acidic protein by the combined activation of PKCdelta and STAT3, offering new lines of therapeutic investigations...
  44. pmc Proteoglycans and osteolysis
    Marc Baud'huin
    INSERM, UMR 957, Nantes, France
    Methods Mol Biol 836:323-37. 2012
    ..After a brief description of the principal osteoclastogenesis assays, the present chapter summarizes the main data published on the effect of PGs/GAGs on bone cells and their functional incidence on osteolysis...
  45. doi request reprint Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis
    Marc Baud'huin
    INSERM, UMR 957, Equipe Labellisée LIGUE 2012, 1 rue Gaston Veil, 44035 Nantes, France Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Universite de Nantes, Nantes Atlantique Universites, EA3822, 1 rue Gaston Veil, 44035 Nantes, France Nantes University Hospital, Nantes, France
    Bone 94:10-21. 2017
    ..These findings strongly support that targeting epigenetic chromatin regulators such as BET proteins may offer a promising alternative for the treatment of bone-related disorders such as osteoporosis...
  46. doi request reprint Bone Morphogenetic Protein 2 and Transforming Growth Factor β1 Inhibit the Expression of the Proinflammatory Cytokine IL-34 in Rheumatoid Arthritis Synovial Fibroblasts
    Marguerite Chemel
    Equipe Labellisée Ligue Contre le Cancer 2012, INSERM, UMR 957, Nantes, France Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Universite de Nantes, Nantes, France CHU Hôtel Dieu, Nantes, France
    Am J Pathol . 2016
    ..This work identifies TGF-β1 and BMP-2 as potent inhibitors of IL-34 expression in RA synovial fibroblasts. These cytokines, as upstream inhibitors of IL-34, may thus contribute to antagonize inflammation and bone erosions in RA...
  47. pmc L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer
    Kevin Biteau
    INSERM, UMR 957, Equipe Ligue Contre le Cancer 2012Nantes, F 44035, France Université de NANTES, Faculte de Medecine, Laboratoire De Physiopathologie De La Résorption Osseuse Et Thérapie Des Tumeurs Osseuses PrimitivesNantes, F 44035, France
    Am J Cancer Res 6:677-89. 2016
    ..This study evidenced for the first time a significant inhibition of primary osteosarcoma progression when both drugs are combined. This result constitutes a first proof-of-principle for clinical application in osteosarcoma patients. ..
  48. doi request reprint IL-34 and M-CSF form a novel heteromeric cytokine and regulate the M-CSF receptor activation and localization
    Aude I Segaliny
    INSERM, UMR 957, Equipe Ligue 2012, Nantes F 44035, France Université de NANTES, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, France
    Cytokine 76:170-81. 2015
    ..This study establishes a new foundation for the understanding of the functional relationship between IL-34 and M-CSF, and gives a new vision for the development of therapeutic approaches targeting the IL-34/M-CSF/M-CSFR axis. ..
  49. pmc ΔNp63α Silences a miRNA Program to Aberrantly Initiate a Wound-Healing Program That Promotes TGFβ-Induced Metastasis
    Lidia Rodriguez Calleja
    INSERM, UMR S 957, Nantes, Equipe Labellisée LIGUE 2012, France Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Universite de Nantes, Nantes Atlantique Universites, rue Gaston Veil, Nantes, France
    Cancer Res 76:3236-51. 2016
    ..Cancer Res; 76(11); 3236-51. ©2016 AACR. ..
  50. doi request reprint Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment
    Aude I Segaliny
    INSERM, UMR 957, Equipe LIGUE Nationale Contre le Cancer 2012, Nantes, 44035, France Université de NANTES, Nantes Atlantique Universites, Pathophysiology of Bone Resorption and Therapy of Primary Bone Tumours, Nantes, France
    Int J Cancer 137:73-85. 2015
    ..By promoting new vessel formation and extravasation of immune cells, IL-34 may play a key role in tumor development and inflammatory diseases...
  51. pmc Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models
    Bérengère Gobin
    INSERM, UMR 957, Nantes, France Université de NANTES, Nantes Atlantique Universites, Physiopathologie de la Resorption Osseuse et Therapie des Tumeurs Osseuses Primitives, Nantes, France
    PLoS ONE 9:e90795. 2014
    ..In the light of the present study and the literature, it would be particularly interesting to revisit therapeutic evaluation of imatinib mesylate in osteosarcoma according to the tyrosine-kinase receptor status of patients. ..
  52. doi request reprint New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance
    David Monderer
    1 INSERM, UMR 957, Equipe Labellisée LIGUE 2012, Nantes, France 2 Université de Nantes, Nantes Atlantique Universites, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France 3 Atlantic Bone Screen ABS, St Herblain, France
    Lab Invest 93:1100-14. 2013
    ..Therefore, 3D chondrogenic cell pellets constitute a more relevant model to study chondrosarcoma chemoresistance and may be a valuable alternative to animal experimentations. ..
  53. doi request reprint Oxytocin reverses ovariectomy-induced osteopenia and body fat gain
    Guillaume E Beranger
    University of Nice Sophia Antipolis G E B, D F P, M D, G A, E Z A and Centre National de la Recherche Scientifique CNRS G B, D F P, M D, G A, E Z A, Institut de Biologie Valrose iBV, Unite Mixte de Recherché UMR 7277, 06100 Nice, France Institut National de la Sante et de la Recherche Medicale INSERM G E B, D F P, M D, G A, E Z A, iBV, U1091, 06100 Nice, France University of Paris Diderot J C, S L, Sorbonne Paris Cité, Unité de Biologie Fonctionnelle et Adaptative BFA UMR 8251, CNRS, F 75205 Paris, France University of Nantes S B, J A, D H, INSERM, UMR 957, Nantes, Psychosomatics/Psychotherapy
    Endocrinology 155:1340-52. 2014
    ..Thus, OT constitutes an effective strategy for targeting osteopenia, overweight, and fat mass redistribution without any detrimental effects in a mouse model mimicking the menopause. ..
  54. ncbi request reprint Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival
    Francois Gouin
    INSERM, ERI 7, Nantes, France
    Int J Cancer 119:980-4. 2006
    ..Because of these first results, new therapeutic approaches of chondrosarcoma must be considered, mainly for low grade chondrosarcoma when disabling operation is planned and when only intralesional resection can be undertaken...
  55. pmc Constitutive expression of TNF-related activation-induced cytokine (TRANCE)/receptor activating NF-κB ligand (RANK)-L by rat plasmacytoid dendritic cells
    Thomas Anjubault
    INSERM UMR 1064, Nantes, France
    PLoS ONE 7:e33713. 2012
    ..Despite this TRANCE/RANKL expression, we were unable to demonstrate in vitro osteoclastogenesis activity for rat pDC. Taken together, these data identifies pDC as novel source of TRANCE/RANKL in the immune system...
  56. pmc A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis
    Benoit Le Goff
    INSERM UMR S 957, 1 rue Gaston Veil, 44035, Nantes Cedex 1, France
    Arthritis Res Ther 11:R185. 2009
    ..We hypothesized that MTX and ZA could have an additive effect to prevent both bone erosion and systemic bone loss...
  57. doi request reprint Severe compromise of preosteoblasts in a surgical mouse model of bisphosphonate-associated osteonecrosis of the jaw
    Luis A Córdova
    INSERM, UMR 957, Equipe Ligue Contre le Cancer 2012, 1 rue Gaston Veil, Nantes Cedex 1, 44035, Nantes, France University of Nantes, Nantes Atlantique Universities, Pathophysiology of Bone Resorption and Therapy of Primary Bone Tumours Laboratory, 1 rue Gaston Veil, Nantes Cedex 1, 44035, Nantes, France Department of Oral and Maxillofacial Surgery, San Borja Arriarán University Hospital Faculty of Dentistry, University of Chile, Sergio Livingstone Polhammer 943, Independencia, Santiago, Chile Electronic address
    J Craniomaxillofac Surg 44:1387-94. 2016
    ..We assessed the effects of zoledronic acid (ZOL) on bone and vascular cells of the alveolar socket using a mouse model of BONJ...
  58. doi request reprint miRNA-193a-5p repression of p73 controls Cisplatin chemoresistance in primary bone tumors
    Camille Jacques
    INSERM, UMR 957, Equipe Labellisée LIGUE 2012, 1 rue Gaston Veil, Nantes, France
    Oncotarget . 2016
    ....
  59. pmc Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration
    Guillaume Odri
    INSERM, Equipe Ligue Contre le Cancer 2012, UMR 957, Nantes F 44035, France
    BMC Cancer 14:169. 2014
    ..However, no data are available on lung metastasis. Therefore, the aim of this study was to determine the effect of ZA on ES cell invasion and metastatic properties...
  60. doi request reprint Osteoblastic and osteoclastic differentiation of human mesenchymal stem cells and monocytes in a miniaturized three-dimensional culture with mineral granules
    Anne Laure Gamblin
    INSERM, UMR957, Nantes, France
    Acta Biomater 10:5139-47. 2014
    ..This 3-D culture may make it possible to test the effects of new drugs for bone healing, osteoporosis and osteosarcomas, in more appropriate cell-cell and cell-matrix interactions than conventional 2-D cultures. ..
  61. ncbi request reprint mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours
    Benjamin Ory
    INSERM ERI 7, Faculte de Medecine, 1 rue Gatson Veil, 44035 Nantes cedex 1, F 44035 France
    Curr Med Chem 14:1381-7. 2007
    ..The present survey describes these two molecular families and discusses their therapeutic interests for primary bone tumours and bone metastases...
  62. doi request reprint A functional, new short isoform of death receptor 4 in Ewing's sarcoma cell lines may be involved in TRAIL sensitivity/resistance mechanisms
    Gaëlle Picarda
    1INSERM, Equipe labellisee LIGUE 2012 UMR 957, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, EA3822, Nantes, France
    Mol Cancer Res 10:336-46. 2012
    ..The results presented in this study showed that DR4, both as the complete form or as its new short isoform, is involved in TRAIL sensitivity in ES...
  63. ncbi request reprint Proteoglycans: key partners in bone cell biology
    Francois Lamoureux
    EA3822 INSERM ERI7, Physiopathologie de la Resorption Osseuse et Therapie des Tumeurs Osseuses Primitives, Faculte de Medecine, 1 rue Gaston Veil, 44035 Nantes cedex 1, France
    Bioessays 29:758-71. 2007
    ..Finally, the potential therapeutic interest of PGs is discussed based on recent data, more particularly on bone tumor-associated osteolysis as these molecules are involved both in bone resorption and tumor development...
  64. ncbi request reprint IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology
    Steeve Kwan Tat
    Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Faculte de Medecine, 1 rue Gaston Veil, BP 53508, 44035 Nantes 1, France
    Cytokine Growth Factor Rev 15:49-60. 2004
    ..The interactions between these three groups are presented within the framework of bone resorption pathophysiology such as tumor associated osteolysis. The central role of the OPG/RANK/RANKL triad is pointed out...
  65. doi request reprint TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models
    Romain Guiho
    INSERM, UMR 957, Equipe Labellisée Ligue Contre le Cancer 2012, Nantes, F 44035, France
    Int J Cancer 139:2802-2811. 2016
    ....
  66. pmc Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases
    Audrey Lamora
    INSERM, UMR 957, Equipe Labellisée Ligue Contre le Cancer 2012, Nantes, France
    Oncotarget 6:14413-27. 2015
    ..Using halofuginone may be a promising therapeutic strategy against tumor progression of osteosarcoma specifically against lung metastases dissemination. ..
  67. doi request reprint Skeletal consequences of RANKL-blocking antibody (IK22-5) injections during growth: mouse strain disparities and synergic effect with zoledronic acid
    Frederic Lezot
    INSERM, UMR 957, Equipe LIGUE Nationale Contre le Cancer 2012, Nantes F 44035, France Université de NANTES, Faculte de Medecine, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes F 44035, France Electronic address
    Bone 73:51-9. 2015
    ..A synergic effect of both bone resorption inhibitors was also demonstrated...
  68. ncbi request reprint Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice
    Benjamin Ory
    Universite de Nantes EA 3822 INSERM ERI 7, Physiopathologie de la Resorption Osseuse et Therapie des Tumeurs Osseuses Primitives, Faculte de Medecine, Nantes, France
    Cancer 104:2522-9. 2005
    ..The effect of zoledronic acid (ZOL) was examined in vivo on lung metastasis progression and animal survival, and in vitro on the cellular mechanisms involved...
  69. doi request reprint Preclinical evidence of potential craniofacial adverse effect of zoledronic acid in pediatric patients with bone malignancies
    Frederic Lezot
    INSERM, UMR 957, Nantes, F 44035, France Université de Nantes Nantes Atlantique Université, Faculte de Medecine, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes F 44035, France
    Bone 68:146-52. 2014
    ..High doses of ZOL irreversibly disturbed teeth eruption and elongation, and delayed skull bone formation. These preclinical observations are essential for the follow-up of onco-pediatric patients treated with ZOL. ..
  70. doi request reprint Novel RANK antagonists for the treatment of bone-resorptive disease: theoretical predictions and experimental validation
    Stephane Teletchea
    INSERM, UMR 957, Equipe Labellisée LIGUE 2012, Universite de Nantes, Laboratory of the Physiopathology of Bone Resorption and Therapy of Primary Bone Tumors LPRO, Nantes, France
    J Bone Miner Res 29:1466-77. 2014
    ....
  71. pmc Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma
    Francois Lamoureux
    Universite de Nantes, Nantes Atlantique Universites, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes F 44035, France INSERM, UMR 957, Nantes F 44035, France LUNAM Université Equipe labellisée LIGUE 2012, Nantes, Cedex
    Oncotarget 5:7805-19. 2014
    ..We hypothesized that targeting CLU using siRNA or the antisense drug, OGX-011, will suppress treatment-induced CLU induction and enhance ZOL-induced cell death in osteosarcoma (OS) cells...
  72. doi request reprint Osteoclasts in RA: diverse origins and functions
    Benoit Le Goff
    Service de Rhumatologie, Hotel Dieu, 1, Place Alexis Ricordeau, 44093 Nantes Cedex 1, France LUNAM Université, 44000 Nantes, France INSERM, UMR957, Physiopathologie de la Resorption Osseuse et Therapie des Tumeurs Osseuses Primitives, 44035 Nantes, France Université de NANTES, Nantes Atlantique Universites, 44035 Nantes, France Electronic address
    Joint Bone Spine 80:586-91. 2013
    ..Research into these interactions may identify new targets for treatments against the bone abnormalities associated with chronic inflammatory disease. ..
  73. doi request reprint Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle
    Francois Lamoureux
    1 INSERM, UMR 957, Equipe Labellisée LIGUE 2012, 1 rue Gaston Veil, Nantes 44035, France 2 Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Universite de Nantes, Nantes Atlantique Universites, EA3822, 1 rue Gaston Veil, Nantes 44035, France 3
    Nat Commun 5:3511. 2014
    ..Collectively, our data indicate that JQ1 is a potent inhibitor of osteoblast and osteoclast differentiation as well as bone tumour development. ..
  74. doi request reprint OPG, RANK and RANK ligand expression in thyroid lesions
    Marie Françoise Heymann
    INSERM, ERI 7, Nantes, F 44035, France
    Regul Pept 148:46-53. 2008
    ..Thus OPG/RANK/RANKL molecular triad might play a role during pathogenesis of follicular and parafollicular tumors...
  75. ncbi request reprint Osteosarcoma: current status of immunotherapy and future trends (Review)
    Kanji Mori
    Université de Nantes EA 3822, INSERM ERI 7, Physiopathologie de la Resorption Osseuse et Therapie des Tumeurs Osseuses Primitives, Faculte de Medecine, 44035 Nantes cedex 1, France
    Oncol Rep 15:693-700. 2006
    ..Immunotherapy for osteosarcomas has great potential, promising improvement in the survival rate and better quality of life for the patients...
  76. doi request reprint Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats
    Camille Chauvin
    Institut National de la Sante et de la Recherche Medicale, U643, CHU Nantes, Institut de Transplantation et de Recherche en Transplantation Urologie Néphrologie, IUN, Universite de Nantes, Faculte de Medecine, France
    Cancer Res 68:9433-40. 2008
    ....
  77. ncbi request reprint Differentiation of osteoblasts from mouse embryonic stem cells without generation of embryoid body
    Laurence Duplomb
    INSERM, ERI 7, Nantes, 44035, France
    In Vitro Cell Dev Biol Anim 43:21-4. 2007
    ..In this manuscript, we showed that mouse embryonic stem cells have the capacity to differentiate spontaneously into osteoblasts, which can be visualized by the appearance of mineralization nodules and osteogenic markers...
  78. doi request reprint Overexpression of smad7 blocks primary tumor growth and lung metastasis development in osteosarcoma
    Audrey Lamora
    INSERM, UMR 957, Equipe Labellisée Ligue Contre le Cancer 2012, Nantes, France Université de NANTES, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France CHU Hôtel Dieu, Nantes, France Inserm Liliane Bettencourt School, Paris, France
    Clin Cancer Res 20:5097-112. 2014
    ....
  79. pmc IL-1β and TNFα promote monocyte viability through the induction of GM-CSF expression by rheumatoid arthritis synovial fibroblasts
    Christelle Darrieutort-Laffite
    INSERM, UMR 957, 44035 Nantes, France Rheumatology Unit, Nantes University Hospital, 44093 Nantes, France Université de NANTES, Nantes Atlantique Universites, Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Faculte de Medecine, 44035 Nantes, France
    Mediators Inflamm 2014:241840. 2014
    ..SF could be a source of cytokines and growth factors driving macrophages survival and activation. Here, we studied the effect of SF on monocyte viability and phenotype...
  80. ncbi request reprint Bisphosphonates: new therapeutic agents for the treatment of bone tumors
    Dominique Heymann
    Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives Faculté de Médecine, 1 rue Gaston Veil, 44035 Nantes 1, France
    Trends Mol Med 10:337-43. 2004
    ..However, results from clinical trials are conflicting, and whether BPs possess anti-cancer effects or not remains controversial...
  81. pmc Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis
    Eva Grimaud
    Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Faculte de Medecine, Centre Hospitalier Universitaire, 1 rue Gaston Veil, 44035 Nantes Cedex, France
    Am J Pathol 163:2021-31. 2003
    ..To define the veracity of RANKL/OPG index in assessing and managing patients with severe osteolysis, an extended population of patients suffering from severe osteolysis must be now monitored...
  82. ncbi request reprint Pharmacodynamics of bisphosphonates in arthritis
    Benoit Le Goff
    INSERM UMR S957, Physiopathologie de la Resorption Osseuse et Therapie des Tumeurs Osseuses Primitives, Faculte de Medecine, 1 rue Gaston Veil, 44035 Nantes cedex 1, France
    Expert Rev Clin Pharmacol 4:633-41. 2011
    ..If their indication in the prevention of glucocorticoid-induced osteoporosis is clear, any beneficial effects on bone erosions are still controversial but interesting preliminary results warrant further investigations...
  83. doi request reprint Carotid and femoral atherosclerotic plaques show different morphology
    Fanny Herisson
    INSERM, U957, Nantes F 44000, France
    Atherosclerosis 216:348-54. 2011
    ..We hypothesized that these differences may be related to the plaque features. To explore this hypothesis, we designed a prospective study that compared carotid and femoral atheroma...
  84. ncbi request reprint Concise review: embryonic stem cells: a new tool to study osteoblast and osteoclast differentiation
    Laurence Duplomb
    INSERM, ERI 7 Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, EA3822, 1 rue Gaston Veil, 44035 Nantes cedex 1
    Stem Cells 25:544-52. 2007
    ..The aim of this review is to present recent discoveries and advances in the differentiation of both osteoblasts and osteoclasts from ES cells...
  85. ncbi request reprint Extraosseous bone formation obtained by association of mesenchymal stem cells with a periosteal flap in the rat
    Pierre Perrot
    INSERM ERI 7, F 44035 Nantes, France
    Ann Plast Surg 59:201-6. 2007
    ....
  86. pmc Molecular alterations associated with osteosarcoma development
    Kosei Ando
    INSERM, UMR S 957, 1 rue Gaston Veil, 44035 Nantes, France
    Sarcoma 2012:523432. 2012
    ..The understanding of the mechanism of molecular alterations can provide the identification of novel therapeutic targets and/or prognostic markers for osteosarcoma treatment to improve the clinical outcome...
  87. pmc Distinct roles of Bcl-2 and Bcl-Xl in the apoptosis of human bone marrow mesenchymal stem cells during differentiation
    Lisa Oliver
    INSERM, UMR 892, Equipe Labellisée Ligue contre le Cancer, Nantes, France
    PLoS ONE 6:e19820. 2011
    ..Adult mesenchymal stem cells (MSCs) can be maintained over extended periods of time before activation and differentiation. Little is known about the programs that sustain the survival of these cells...
  88. pmc Modulatory effects of proteoglycans on proteinase activities
    Steven Georges
    INSERM, U957, Nantes, France
    Methods Mol Biol 836:307-22. 2012
    ..Understanding the modulatory effects exerted by PGs on proteinase activities is expected to lead to new insights in the understanding of some molecular systems present in pathological states, providing new targets for drug therapy...
  89. ncbi request reprint Recent advances in TGF-beta effects on chondrocyte metabolism. Potential therapeutic roles of TGF-beta in cartilage disorders
    Eva Grimaud
    Laboratoire de Physiopathologie de la Résorption Osseuse EE 99 01, Faculte de Medecine, University of Nantes, 1 rue Gaston Veil, 44035 Nantes, France
    Cytokine Growth Factor Rev 13:241-57. 2002
    ..In vivo induction of the expression of TGF-beta and the use of gene transfer may provide a new approach for treatment of osteoarthritic lesions...
  90. pmc The vertebral interbody grafting site's low concentration in osteogenic progenitors can greatly benefit from addition of iliac crest bone marrow
    Mostafa Romih
    Department of Orthopaedic Surgery, Hotel Dieu, University Hospital of Nantes, 44093 Nantes, France
    Eur Spine J 14:645-8. 2005
    ..001) and vertebral body (P<0.01), especially at the time of graft implantation. In light of our results, we advocate addition of iliac crest bone marrow aspirate to increase the success rate of vertebral interbody fusion...